Avadel Pharmaceuticals (AVDL) Return on Equity (2016 - 2022)
Historic Return on Equity for Avadel Pharmaceuticals (AVDL) over the last 14 years, with Q3 2022 value amounting to 2.93%.
- Avadel Pharmaceuticals' Return on Equity rose 35500.0% to 2.93% in Q3 2022 from the same period last year, while for Sep 2022 it was 2.93%, marking a year-over-year increase of 35500.0%. This contributed to the annual value of 0.71% for FY2021, which is 6200.0% down from last year.
- According to the latest figures from Q3 2022, Avadel Pharmaceuticals' Return on Equity is 2.93%, which was up 35500.0% from 1.88% recorded in Q2 2022.
- Avadel Pharmaceuticals' Return on Equity's 5-year high stood at 28.25% during Q1 2019, with a 5-year trough of 51.18% in Q1 2020.
- For the 5-year period, Avadel Pharmaceuticals' Return on Equity averaged around 0.82%, with its median value being 0.21% (2020).
- Its Return on Equity has fluctuated over the past 5 years, first plummeted by -794300bps in 2020, then soared by 511800bps in 2021.
- Quarter analysis of 5 years shows Avadel Pharmaceuticals' Return on Equity stood at 2.78% in 2018, then skyrocketed by 197bps to 2.71% in 2019, then plummeted by -99bps to 0.04% in 2020, then tumbled by -2666bps to 1.0% in 2021, then skyrocketed by 395bps to 2.93% in 2022.
- Its last three reported values are 2.93% in Q3 2022, 1.88% for Q2 2022, and 1.08% during Q1 2022.